1.1.................... moves to amend S.F. No. 4410, the first unofficial engrossment, as follows:
1.2Page 365, after line 33, insert:

1.4    Subdivision 1. Establishment. The Minnesota Board of Pharmacy shall establish a
1.5pharmacogenomics (PGx) task force to evaluate and assess the current availability of
1.6pharmacogenomics statewide and to develop recommendations for making
1.7pharmacogenomics available statewide. For purposes of this section, "pharmacogenomics"
1.8means the determination of how variation in an individual's genomic information influences
1.9medication safety and efficacy.
1.10    Subd. 2. Membership. (a) The PGx task force shall consist of members appointed by
1.11the executive director of the Minnesota Board of Pharmacy according to paragraph (c) and
1.12four members of the legislature appointed according to paragraph (e). Members shall serve
1.13for a term of two years.
1.14(b) The task force will elect a chair and cochair and other officers as the members deem
1.15necessary, selected from among the appointed members.
1.16(c) The executive director shall appoint the following members:
1.17(1) at least two pharmacists with expertise in pharmacogenomics from the University
1.18of Minnesota;
1.19(2) at least two other pharmacists licensed and practicing within the state with expertise
1.20in pharmacogenomics;
1.21(3) at least two physicians licensed and practicing in the state;
1.22(4) at least two health system or clinic administrators, or their designees, from the state;
1.23(5) a representative of a patient organization that operates in the state;
2.1(6) a patient or caregiver with an interest in pharmacogenomics;
2.2(7) a pharmacist or other provider who is a member of a diverse and underrepresented
2.4(8) a second member of a diverse and underrepresented community;
2.5(9) a representative of the biotechnology industry;
2.6(10) a representative of payers, health plans, or insurers;
2.7(11) an expert in health informatics from the University of Minnesota;
2.8(12) an expert in data management and security;
2.9(13) an expert in ethical, legal, and social implications of genomics;
2.10(14) an expert in health regulatory affairs from the state; and
2.11(15) a genetic counselor.
2.12(d) Members appointed according to paragraph (c) shall reflect an equitable statewide
2.13geographical representation and representation from diverse groups within the state.
2.14(e) The PGx task force shall include two members of the senate, one appointed by the
2.15majority leader and one appointed by the minority leader, and two members of the house
2.16of representatives, one appointed by the speaker of the house and one appointed by the
2.17minority leader, who shall serve as nonvoting, ex officio members who do not hold a board
2.18office or chair a board committee.
2.19(f) The executive director or a designee shall serve as an ex officio, nonvoting member
2.20of the PGx task force.
2.21(g) Initial appointments to the PGx task force shall be made no later than September 1,
2.23    Subd. 3. Meetings. The first meeting of the PGx task force shall be convened no later
2.24than October 20, 2022. The PGx task force shall meet at the call of the chairperson or at
2.25the request of a majority of PGx task force members.
2.26    Subd. 4. Duties. The PGx task force's duties may include but are not limited to:
2.27(1) conducting a comprehensive analysis of pharmacogenomics across the state;
2.28(2) developing a strategy to implement pharmacogenomics statewide;
3.1(3) determining the pharmacogenomic education needed for health care professionals
3.2to improve effectiveness of treatment and reduce reactions to medications through the use
3.3of pharmacogenomics;
3.4(4) soliciting input from the public on adoption readiness of pharmacogenomics;
3.5(5) considering the needs and perspectives of diverse and underrepresented communities;
3.7(6) developing recommendations for:
3.8(i) disseminating pharmacogenomics services into practice across the state;
3.9(ii) evaluating the benefits and value to patient health as it relates to pharmacogenomics;
3.10(iii) building capacity for research on pharmacogenomics needs and capabilities across
3.11the state;
3.12(iv) necessary education for health care professionals;
3.13(v) public adoption of pharmacogenomics, including the needs of diverse and
3.14underrepresented communities;
3.15(vi) evaluating IT solutions for data sharing across electronic medical records and retail
3.16pharmacy systems;
3.17(vii) identifying and evaluating federal pharmacogenomics legislation for comparison;
3.19(viii) changes to state policy and statutes.
3.20    Subd. 5. Contracts. The Board of Pharmacy may enter into a contract with the University
3.21of Minnesota for conducting research and surveys, or providing administrative assistance
3.22to the task force.
3.23    Subd. 6. Conflict of interest. PGx task force members are subject to state policy on
3.24conflicts of interest.
3.25    Subd. 7. Report required. By October 30, 2023, the executive director shall report to
3.26the chairs and ranking minority members of the legislative committees with jurisdiction
3.27over health care policy on the activities of the PGx task force. At a minimum, the report
3.28must include:
3.29(1) a description of the PGx task force's goals; and
3.30(2) a description of the independent recommendations made by the PGx task force.
4.1    Subd. 8. Expiration. The PGx task force expires October 30, 2024."
4.2Page 870, line 6, delete "175,000" and insert "425,000"
4.3Page 870, line 8, before "Medication" insert "(a)"
4.4Page 870, after line 13, insert:
4.5"(b) PGx Task Force. $250,000 in fiscal year
4.62023 is for the Board of Pharmacy to establish
4.7the pharmacogenomics (PGx) task force. This
4.8is a onetime appropriation. This appropriation
4.9is available until expended."
4.10Page 870, line 27, delete "7,775,000" and insert "7,525,000"
4.11Adjust amounts accordingly
4.12Renumber the sections in sequence and correct the internal references
4.13Amend the title accordingly